160970-07-0 Usage
Description
N-tert-Butyloxycarbonyl Silodosin is a chemical compound that serves as a protected form of Silodosin (S465000), which is an α1a-adrenoceptor antagonist. This modification is typically employed to protect the functional groups of the molecule during synthesis, allowing for further chemical reactions to be carried out without affecting the core structure of Silodosin.
Uses
Used in Pharmaceutical Industry:
N-tert-Butyloxycarbonyl Silodosin is used as an intermediate compound for the synthesis of Silodosin, which is an α1a-adrenoceptor antagonist. The application reason is to facilitate the development of pharmaceuticals targeting the α1a-adrenoceptor, which can be used in the treatment of various conditions such as benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
Additionally, the protected form of Silodosin may be used in research and development to study the interactions of α1a-adrenoceptor antagonists with their target receptors, potentially leading to the discovery of new therapeutic agents with improved efficacy and reduced side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 160970-07-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,9,7 and 0 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 160970-07:
(8*1)+(7*6)+(6*0)+(5*9)+(4*7)+(3*0)+(2*0)+(1*7)=130
130 % 10 = 0
So 160970-07-0 is a valid CAS Registry Number.
160970-07-0Relevant articles and documents
PROCESS FOR THE PREPARATION OF INDOLINE COMPOUND
-
, (2018/06/22)
The present invention relates to an improved process for the preparation of Silodosin (I) which is useful in the treatment of Benign Prostate Hyperplasia (BPH) and related disorders. The present invention also relates to the purification process resulting in substantially pure Silodosin.
1,5,7-trisubstituted indoline compounds and salts thereof
-
, (2008/06/13)
Indoline compounds represented by the formula: STR1 wherein R represents a saturated or unsaturated aliphatic acyl group which may have one or more halogen atoms, a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group or an aryl group as substituents; a hydroxyalkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group having a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl substituted lower alkoxycarbonyl group, a carbamoyl group, a mono- or dialkyl substituted carbamoyl group or a cyano group as substituents; an aromatic acyl group which may have one or more halogen atoms as substituents; a furoyl group or a pyridylcarbonyl group; R1 represents a lower alkyl group which may have one or more halogen atoms or an aryl group as substituents; and pharmaceutically acceptable salts thereof, exhibit a selective suppressive action on urethral contractions, and thus are useful as therapeutic agents for the treatment of dysuria with less hypotension including postural hypotension.
